Fortrea Holdings (FTRE) Receivables (2022 - 2026)
Fortrea Holdings (FTRE) reported Receivables of $619.6 million for Q1 2026, down 15.01% on a YoY basis from $729.0 million in Q1 2025, and up 5.07% quarter-over-quarter from $589.7 million in Q4 2025.
Fortrea Holdings (FTRE) Receivables (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Receivables for 5 years, with the latest figure at $619.6 million in Q1 2026.
- For the quarter ending Q1 2026, Receivables fell 15.01% year-over-year to $619.6 million; the trailing twelve-month figure through Mar 2026 stood at $619.6 million (down 15.01% YoY), and the FY2025 full-year result was $589.7 million, down 10.58% from the prior year.
- Receivables for Q1 2026 stood at $619.6 million, up from $589.7 million in the prior quarter.
- The five-year high for Receivables was $1.0 billion in Q3 2023, with the low at $244.5 million in Q2 2025.
- Historically, Receivables has averaged $715.0 million across 5 years, with a median of $663.2 million in 2025.
- The largest YoY upside for Receivables was 86.97% in 2025 against a maximum downside of 61.67% in 2025.
- Fortrea Holdings' Receivables stood at $1.0 billion in 2022, then dropped by 3.3% to $988.5 million in 2023, then slumped by 33.28% to $659.5 million in 2024, then retreated by 10.58% to $589.7 million in 2025, then advanced by 5.07% to $619.6 million in 2026.
- The last three Receivables figures came in at $619.6 million (Q1 2026), $589.7 million (Q4 2025), and $663.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 13.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.00 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 619.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 619.60 Mn |
| Dec 31, 2025 | 589.70 Mn |
| Sep 30, 2025 | 663.20 Mn |
| Jun 30, 2025 | 244.50 Mn |
| Mar 31, 2025 | 729.00 Mn |
| Dec 31, 2024 | 659.50 Mn |
| Sep 30, 2024 | 689.10 Mn |
| Jun 30, 2024 | 637.90 Mn |
| Mar 31, 2024 | 389.90 Mn |
| Dec 31, 2023 | 988.50 Mn |
| Sep 30, 2023 | 1.05 Bn |
| Jun 30, 2023 | 1.01 Bn |
| Dec 31, 2022 | 1.02 Bn |